Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma

Haematologica

Volumn 90, Issue 10, 2005, Pages 1422-1432

  Van Agthoven, Michel ^a   Kramer, Mark H H ^b   Sonneveld, Pieter ^a   Van Der Hem, Klaas G ^c   Huijgens, Peter C ^d   Wijermans, Pierre W ^e   Kluin Nelemans, Hanneke C ^f   Schaafsma, M Ronald ^g   Biesma, Douwe H ^h   Mattijssen, Vera ⁱ   Uyl De Groot, Carin A ^a   Hagenbeek, Anton ^j  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

^c ZAANS MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEYENBURG HOSPITAL   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g MEDISCH SPECTRUM TWENTE   (Netherlands)

^h ST ANTONIUS HOSPITAL   (Netherlands)

ⁱ RIJNSTATE HOSPITAL   (Netherlands)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

Antineoplastic combined chemotherapy protocols; Cost and cost analysis; Economics; Follicular lymphoma; Non Hodgkin's lymphoma

Indexed keywords

ALPHA INTERFERON; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEALTH CARE COST; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; RESOURCE MANAGEMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 27144514933     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Gupta RK, Lister TA. Current management of follicular lymphoma. Curr Opin Oncol 1996;8:360-5.
2. The Non-Hodkgin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18.
3. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13:140-7.
4. Rohatiner A. Follicle centre cell lymphoma: optimal use of therapeutic options. Ann Oncol 2000;11:111-5.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - version 1.2005: Non-Hodgkin's Lymphoma. 2005. http://www.nccn.org, Accessed: July 18, 2005.
6. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95.
7. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
8. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14:1282-90.
9. Soubeyran P, Debled M, Tchen N, Richaud P, Monnereau A, Bonichon F, et al. Follicular lymphomas - a review of treatment modalities. Crit Rev Oncol Hematol 2000;35:12-32.
10. Linch D. Current treatment of follicular and low-grade non-Hodgkin's lymphoma. Anticancer Drugs 2001;12 Suppl 2:S5-9.
11. Coffey J, Hodgson DC, Gospodarowicz MK. Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S28-36.
12. MacManus MP, Seymour JF. Management of localized low-grade follicular lymphomas. Australas Radiol 2001;45: 326-34.
13. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21: 2115-22.
14. Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO. Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park) 2005;19:213-28.
15. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311:1471-5.
16. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;62:516-22.
17. Rohatiner AZ, Lister TA. The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 2005;18:1-10.
18. Brandt L, Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol 2001;40:213-23.
19. Archuleta TD, Armitage JO. Advances in follicular lymphoma. Semin Oncol 2004;31:66-71.
20. Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004;101:883-93.
21. Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma 2003;44 Suppl 4:S37-47.
22. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23.
23. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-71.
24. Lemieux B, Coiffier B. Radio-immunotherapy in low-grade non-Hodgkin's lymphoma. Best Pract Res Clin Haematol 2005;18:81-95.
25. Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23: 2215-23.
26. Tse WW, Lazarus HM, Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant 2004;34:929-38.
27. Finke J. The role of stem cell transplantation in the treatment of follicular lymphoma. Semin Cancer Biol 2003; 13:233-9.
28. Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005;105:3817-23.
29. Peggs KS, Mackinnon S, Linch DC. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 2005;128:153-68.
30. Mounier N, Socie G, Gisselbrecht C. High-dose therapy for indolent lymphoma. Crit Rev Oncol Hematol 2002; 41:225-39.
31. Sweetenham J, Hieke K, Kerrigan M, Howard P, Smartt PF, McIntyre AM, et al. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. Br J Haematol 1999;106:47-54.
32. Herold M, Sacchi S, Hieke K. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use. Haematologica 2002;87: 719-29.
33. van Agthoven M, Uyl-de Groot CA, Sonneveld P, Hagenbeek A. Economic assessment in the management of non-Hodgkin's lymphoma. Expert Opin Pharmacother 2004;5:2529-2548.
34. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hematol J 2000;1:53-66.
35. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
36. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York/Oxford: Oxford University Press; 1997.
37. van Loenen AC. Pharmaceutical Compass 2003. Amstelveen: Health Care Board; 2003.
38. Snijder S, Coebergh JWW, Otter R, Visser O, Schouten LJ. Hematological malignancies in the Netherlands 1989-1995. Utrecht: Association of Comprehensive Cancer Centres. 1999.
39. HOVON, iMTA, CBO. Guideline Non-Hodgkin's Lymphoma (in Dutch). Alphen aan den Rijn: Van Zuiden Communications BV. 2004.
40. van Agthoven M. Economic evaluations in aggressive non-Hodgkin's lymphoma (Thesis). Rotterdam: Optima Grafische Communicatie BV. 2004.
41. van Agthoven M, Groot MT, Verdonck LF, Lowenberg B, Schattenberg AV, Oudshoorn M, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002;30:243-51.
42. Barosi G, Marchetti M, Alessandrino P, Locatelli F, Casula S, Lunghi M, et al. A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 1999;23:719-25.
43. van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease, a prospective randomised trial. Eur J Cancer 2001;37: 1781-9.
44. Bremer K. Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study. Anticancer Drugs 2003;14:809-15.
45. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-61.
46. rd, Scullin DC Jr, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7.
47. Schulman K, Burke J, Drummond M, Davies L, Carlsson P, Gruger J, et al. Resource costing for multinational neurologic clinical trials: methods and results. Health Econ 1998;7:629-38.
48. Smith DH, Adams JR, Johnston SR, Gordon A, Drummond MF, Bennett CL. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 2002; 13:1590-7.
49. Bennett CL, Armitage JL, LeSage S, Gulati SC, Armitage JO, Gorin NC. Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells 1994;12:424-9.
50. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997;90: 4201-5.
51. Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999;34:129-36.
52. Gandhi MK, Marcus RE. Follicular lymphoma: time for a re-think? Blood Rev 2005;19:165-78.